Bloomberg Intelligence

Biogen Was The Train Wreck Everyone Saw Coming: Nisen (Podcast)

Share this episode
Anyone with this link can open it.
Share Link
Start at 0:00

This episode isn’t summarized yet

Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.

Show notes

Max Nisen, Bloomberg Opinion health care columnist, on Biogen plunging after the company and its partner Eisai announced it was halting their Alzheimer drug trial. Gad Levanon, Chief Economist: North America at the Conference Board, on the February Leading Index and the Fed decision. Bill Zox, CIO of Fixed income at Diamond Hill Capital Management, to discuss the Fed, the fixed income markets and where he sees opportunities.  Chen Grazutis, Apparel and Footwear Analyst from Bloomberg Intelligence, on the valuation for Levi Strauss IPO. Hosted by Lisa Abramowicz and Paul Sweeney. 

See omnystudio.com/listener for privacy information.

Couldn't load the audio. A blocker may be stopping the show's tracking links. Open the file